 |
|
New biomarker predicts response to hepatitis C treatment
August 17, 2009DURHAM, N.C. - Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. Duke University Medical Center scientists says the biomarker not only predicts who is most likely to respond to treatment and who isn't, but also may explain why there are such different rates of response among racial and ethnic groups, a phenomenon that has puzzled physicians for years.
"For geneticists, understanding response to treatment for hepatitis C infection has been almost like a Holy Grail," says David Goldstein, Ph.D., director of the Center for Human Genome Variation in Duke's Institute for Genome Sciences & Policy and the senior author of the study. "The side effects of hepatitis treatment can be brutal, and about half the time, the treatment fails to eradicate the virus. This discovery enables us to give patients valuable information that will help them and their doctors decide what is best for them. This is what personalized medicine is all about."
The discovery is reported online in the journal Nature.
Hepatitis C is one of the most common infections in the world, affecting an estimated 170 million people. Many can live with the disease for years without any serious complications. About a quarter of the time, however, the infection leads to cirrhosis of the liver, which, in turn, can lead to liver cancer or death or the need for a transplant. Hepatitis C is the leading cause for liver transplants in the U.S.
Treatment typically involves 48 weeks of interferon plus the antiviral drug ribavirin. Some patients develop such taxing side effects that they stop treatment. Physicians have long observed that African-Americans are less likely to respond to treatments than Caucasians, while East Asian patients seem to respond the best. But until now, no one has known why.
"This discovery appears to explain a large part of it. It is most certainly a triumph of translational medicine," says John McHutchison, M.D., associate director of the Duke Clinical Research Institute, a member of the Division of Gastroenterology in the School of Medicine at Duke and study co-author. "This is a perfect example of bedside to bench and back to bedside investigation."
The new marker is a single letter change - a C instead of a T - in a tiny segment of DNA near the IL28B gene. Researchers found it by studying 1671 individuals who participated in the IDEAL study, a multi-center clinical trial that compared the two most widely used therapies among patients with the most common form of the disease in the U.S. and Europe. McHutchison was the lead investigator of the recently published IDEAL study, which found no clinically meaningful differences in overall viral response among the regimens.
In conducting the current study, Goldstein and his colleagues found that the patients who had the single-letter change in their DNA were significantly more likely to respond to treatment than those who did not have it. "Eighty percent of those with the favorable response genotype eradicated the virus, while only about 30 percent with the less favorable response genotype did so. With differences of that magnitude, patients considering therapy may want to know what their genotype is before they start treatment," says Goldstein.
Goldstein says they were struck by the finding that the "good" genotype proved beneficial to patients in all population subgroups. "But because it appears significantly more often among Caucasian populations than it does among African populations, we feel it explains much of the difference in response rates we see between African Americans and those of European ancestry," says Goldstein. "This tells us that individual genetic makeup is much more important determinant of response to treatment than is race or ethnicity."
Researchers found that African Americans with the favorable (CC) genotype had a significantly higher rate of response to treatment (53.3 percent) than did individuals of European ancestry who had the less favorable (TT) genotype (33.3 percent).
The researchers also ran tests to see if the presence of the biomarker was related in any way to viral load, a measure of how much virus was circulating in the patient before treatment started. They found a significant association in all groups. "Interestingly, we found that the C allele, although associated with better treatment response, was associated with a higher viral load at baseline - something we have traditionally viewed as a negative prognostic marker when it comes to treatment response," says McHutchison.
That finding, along with other evidence gleaned in the research, suggests that patients who have the beneficial genetic marker might be especially adept at spontaneously clearing the virus through some as yet unknown mechanism, says McHutchison. "It was thrilling to discover such an important biological marker related to response to hepatitis C treatments, but at the same time, the findings tell us there is a lot more work to do before we can fully understand how patients' immune systems protect them from the virus."
"This stunning finding supports the integration of research efforts that previously were not connected," says Robert Califf, M.D., vice chancellor for clinical research and director of the Duke Translational Medicine Institute. "Drs. Goldstein, McHutchison and colleagues have combined world class genotyping and clinical trials management in an academic medical center with an industry sponsored clinical trial to produce a set of findings that are likely to change practice. Their focus on modification of clinical outcomes is especially important to note as we design future studies."
Some members of the research team are interested in finding a way to routinely test for the new marker, but McHutchison says important work still needs to be done. "This study only pertains to patients with genotype 1 infection. We still need to evaluate the polymorphism among patients with less common genotypes of hepatitis C."
Duke University Medical Center
Hepatitis C is one of the most common infections in the world, affecting an estimated 170 million people. Many can live with the disease for years without any serious complications. About a quarter of the time, however, the infection leads to cirrhosis of the liver, which, in turn, can lead to liver cancer or death or the need for a transplant. Hepatitis C is the leading cause for liver transplants in the U.S.
Treatment typically involves 48 weeks of interferon plus the antiviral drug ribavirin. Some patients develop such taxing side effects that they stop treatment. Physicians have long observed that African-Americans are less likely to respond to treatments than Caucasians, while East Asian patients seem to respond the best. But until now, no one has known why.
"This discovery appears to explain a large part of it. It is most certainly a triumph of translational medicine," says John McHutchison, M.D., associate director of the Duke Clinical Research Institute, a member of the Division of Gastroenterology in the School of Medicine at Duke and study co-author. "This is a perfect example of bedside to bench and back to bedside investigation."
The new marker is a single letter change - a C instead of a T - in a tiny segment of DNA near the IL28B gene. Researchers found it by studying 1671 individuals who participated in the IDEAL study, a multi-center clinical trial that compared the two most widely used therapies among patients with the most common form of the disease in the U.S. and Europe. McHutchison was the lead investigator of the recently published IDEAL study, which found no clinically meaningful differences in overall viral response among the regimens.
In conducting the current study, Goldstein and his colleagues found that the patients who had the single-letter change in their DNA were significantly more likely to respond to treatment than those who did not have it. "Eighty percent of those with the favorable response genotype eradicated the virus, while only about 30 percent with the less favorable response genotype did so. With differences of that magnitude, patients considering therapy may want to know what their genotype is before they start treatment," says Goldstein.
Goldstein says they were struck by the finding that the "good" genotype proved beneficial to patients in all population subgroups. "But because it appears significantly more often among Caucasian populations than it does among African populations, we feel it explains much of the difference in response rates we see between African Americans and those of European ancestry," says Goldstein. "This tells us that individual genetic makeup is much more important determinant of response to treatment than is race or ethnicity."
Researchers found that African Americans with the favorable (CC) genotype had a significantly higher rate of response to treatment (53.3 percent) than did individuals of European ancestry who had the less favorable (TT) genotype (33.3 percent).
The researchers also ran tests to see if the presence of the biomarker was related in any way to viral load, a measure of how much virus was circulating in the patient before treatment started. They found a significant association in all groups. "Interestingly, we found that the C allele, although associated with better treatment response, was associated with a higher viral load at baseline - something we have traditionally viewed as a negative prognostic marker when it comes to treatment response," says McHutchison.
That finding, along with other evidence gleaned in the research, suggests that patients who have the beneficial genetic marker might be especially adept at spontaneously clearing the virus through some as yet unknown mechanism, says McHutchison. "It was thrilling to discover such an important biological marker related to response to hepatitis C treatments, but at the same time, the findings tell us there is a lot more work to do before we can fully understand how patients' immune systems protect them from the virus."
"This stunning finding supports the integration of research efforts that previously were not connected," says Robert Califf, M.D., vice chancellor for clinical research and director of the Duke Translational Medicine Institute. "Drs. Goldstein, McHutchison and colleagues have combined world class genotyping and clinical trials management in an academic medical center with an industry sponsored clinical trial to produce a set of findings that are likely to change practice. Their focus on modification of clinical outcomes is especially important to note as we design future studies."
Some members of the research team are interested in finding a way to routinely test for the new marker, but McHutchison says important work still needs to be done. "This study only pertains to patients with genotype 1 infection. We still need to evaluate the polymorphism among patients with less common genotypes of hepatitis C."
Duke University Medical Center
Hepatitis Current Events and Hepatitis News RSSToward explaining why hepatitis B hits men harder than women
Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.
Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.
Mount Sinai finds those with more difficult to treat forms of HCV are half as likely to get treated
A new study by Mount Sinai researchers has for the first time found that patients with more difficult to treat forms of hepatitis C are half as likely to initiate treatment for the disease, when compared to patients with hepatitis C that is easier to treat.
Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.
Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Liver cells grown from patients' skin cells
Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients' skin cells opening the possibility of treating a wide range of diseases that affect liver function.
Injury and hazards in home health care nursing are a growing concern
Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care.
Medication effective for acute liver failure in early stages of disease
The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.
New aging studies improving vaccine efficacy for the elderly
A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects.
More Hepatitis Current Events and Hepatitis News Articles
 |
Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer (Author) In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition, this comprehensive handbook reveals cutting-edge research on the dangers of hepatitis C, one of the world's fasting-growing microbial threats. |
 |
Living With Hepatitis C For Dummies by Nina L. Paul (Author), Gina Pollichino (Foreword) A comprehensive, empathetic guide for anyone suffering from this serious liver disease Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths–about 8,000 to 10,000 people annually–and is the most common reason for liver transplantation. This compassionate guide explains how hepatitis C affects the liver and the body and provides solid advice on today’s treatment options–from drugs (and their side effects) to transplants and alternative therapies–as well as tips on dealing with the emotional and financial burdens the disease brings with it. Nina L Paul, PhD (New York, NY) earned her doctorate in infectious... |
 |
HEPATITIS GIANT MICROBE by Giant Microbes HAV is spread primarily by unsanitary food and water ? HBV is transmitted in bodily fluids and can cause chronic liver disease ? HCV is perhaps the most dangerous: no vaccine is available ? HDV occurs only in the presence of HBV ? HEV is relatively mild and non-chronic ? HFV and HGV are newly identified; their connection with liver disease is debated |
 |
Understanding Hepatitis C Part of the award winning public television series Healthy Body/Healthy Mind. Hepatitis C is a blood born disease affecting over 5 million Americans. Dangerously, most people infected aren't even aware they've contracted it. On this program, Infectious Disease Specialists discuss the latest scientific & clinical data including treatment options and their side effects. We visit with real people who for years were unaware they were carrying the virus, found out, sought proper treatment and now live virus free. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing by Misha Ruth Cohen O.M.D. L. Ac. (Author), Robert Gish (Author), Kalia Doner (Author) A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no idea they are being attacked by something they can't even detect. Now, the two experts on Hepatitis C who teamed up to write the first comprehensive guide to orthodox and alternative treatment options have revised and fully updated the book to include recent findings in the field. Along with programs for self-care, nutritional and fitness plans and a comprehensive Western and Chinese medical... |
 |
Home Access Hepatitis C Check 1 ea by Home Access At-Home Telemedicine Test Service for Hepatitis C*. Confidentia |
|
Aids & Hepatitis Digest by Ccm International Ltd Provides information to Air Force comptroller personell relating to mission accomplishment, to assist them in solving problems and improving efficiency of operation and to communicate new developments and techniques | |
 |
Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle by Balanceuticals Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. |
 |
Living with Hepatitis C, Fifth Edition: A Survivor's Guide by Gregory T. Everson (Author) The Most Trusted Resource and Reference for Millions of Americans Living with Hepatitis C was the first book to explain in everyday language the causes of this disease, its major and minor symptoms, and all of the latest treatments available. Researchers have continued to make dramatic strides in helping the millions of Americans who suffer from Hepatitis C since the book's first publication, and each new edition has kept up with the most recent findings. The latest revised Living With Hepatitis C, Fifth Edition includes cutting-edge information on: * New treatments including pegylated and consensus interferons * Living-donor transplants * Co-infections with Hepatitis B and HIV/AIDS * Promising new clinical trials of protease and polymerase inhibitors *... |
 |
Understanding Hepatitis Anatomical Chart Laminated (In Stock)-9992PL1.5 by Anatomical Chart Company Defines viral hepatitis and the types of hepatic viruses that cause this disease: Hepatitis A, B, C, D, E, and recently discovered viruses G and TTV (Transfusion Transmitted Virus). Talks about modes of tranmission and illustrated the complications of hepatitis. Illustrates the anatomy of the liver, pancreas and surrounding structures, including veins and arteries. Shows 3 liver biopsies: normal, mild hepatitis and moderate. Lists the signs and symptoms which progress by stages. |
| © 2009 BrightSurf.com |